BRPI0609719B8 - derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2 - Google Patents
derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2Info
- Publication number
- BRPI0609719B8 BRPI0609719B8 BRPI0609719A BRPI0609719A BRPI0609719B8 BR PI0609719 B8 BRPI0609719 B8 BR PI0609719B8 BR PI0609719 A BRPI0609719 A BR PI0609719A BR PI0609719 A BRPI0609719 A BR PI0609719A BR PI0609719 B8 BRPI0609719 B8 BR PI0609719B8
- Authority
- BR
- Brazil
- Prior art keywords
- mgbur2
- acetylenyl
- antagonists
- pyrimidine derivatives
- pyrazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2, bem como processo para a preparação, composição farmacêutica e emprego dos mesmos. a presente invenção refere-se aos compostos da fórmula (1): um processo para a fabricação dos mesmos, seu emprego para a preparação de medicamentos para tratar distúrbios do cns e composições farmacêuticas contendo-os, em que r¹ a r³, a, m, l, e, g, e j são como definidos na descrição e reivindicações.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05102332.3 | 2005-03-23 | ||
EP05102332 | 2005-03-23 | ||
PCT/EP2006/002334 WO2006099972A1 (en) | 2005-03-23 | 2006-03-14 | Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0609719A2 BRPI0609719A2 (pt) | 2010-04-20 |
BRPI0609719B1 BRPI0609719B1 (pt) | 2020-12-01 |
BRPI0609719B8 true BRPI0609719B8 (pt) | 2021-05-25 |
Family
ID=36390306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0609719A BRPI0609719B8 (pt) | 2005-03-23 | 2006-03-14 | derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2 |
Country Status (24)
Country | Link |
---|---|
US (4) | US7238808B2 (pt) |
EP (1) | EP1863818B1 (pt) |
JP (1) | JP4801724B2 (pt) |
KR (2) | KR100973609B1 (pt) |
CN (1) | CN101180299B (pt) |
AR (1) | AR052948A1 (pt) |
AT (1) | ATE460417T1 (pt) |
AU (1) | AU2006226669B2 (pt) |
BR (1) | BRPI0609719B8 (pt) |
CA (1) | CA2602444C (pt) |
CY (1) | CY1110115T1 (pt) |
DE (1) | DE602006012815D1 (pt) |
DK (1) | DK1863818T3 (pt) |
ES (1) | ES2339477T3 (pt) |
IL (1) | IL185692A (pt) |
MX (1) | MX2007011483A (pt) |
NO (1) | NO340078B1 (pt) |
PL (1) | PL1863818T3 (pt) |
PT (1) | PT1863818E (pt) |
RU (1) | RU2412943C2 (pt) |
SI (1) | SI1863818T1 (pt) |
TW (1) | TWI314862B (pt) |
WO (1) | WO2006099972A1 (pt) |
ZA (1) | ZA200708028B (pt) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
ES2403206T3 (es) * | 2005-12-23 | 2013-05-16 | Ariad Pharmaceuticals, Inc. | Compuestos bicíclicos de heteroarilo |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
US7985754B2 (en) * | 2006-07-17 | 2011-07-26 | Trovis Pharmaceuticals, Llc | Selective antagonists of A2A adenosine receptors |
EP2121613A2 (en) | 2007-01-31 | 2009-11-25 | Vertex Pharmaceuticals, Inc. | 2-aminopyridine derivatives useful as kinase inhibitors |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
CA2698929C (en) | 2007-09-14 | 2016-01-19 | Addex Pharma S.A. | 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones |
MY152078A (en) | 2007-09-14 | 2014-08-15 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
MX2010005110A (es) * | 2007-11-14 | 2010-09-09 | Ortho Mcneil Janssen Pharm | Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2. |
WO2009100375A1 (en) | 2008-02-06 | 2009-08-13 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
AU2009218459A1 (en) * | 2008-02-28 | 2009-09-03 | Novartis Ag | Imidazo [1,2-B] pyridazine derivatives for the treatment of C-Met tyrosine kinase mediated disease |
JP2011529062A (ja) | 2008-07-23 | 2011-12-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾロピリジンキナーゼ阻害剤 |
US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
JP5631310B2 (ja) | 2008-07-23 | 2014-11-26 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 三環式ピラゾロピリジンキナーゼ阻害剤 |
JP2011530527A (ja) | 2008-08-06 | 2011-12-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | アミノピリジンキナーゼ阻害剤 |
JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体 |
EP2346505B1 (en) | 2008-10-16 | 2014-04-23 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
CN102232074B (zh) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物 |
MX2011011653A (es) | 2009-05-06 | 2012-01-20 | Vertex Pharma | Pirazolopiridinas. |
MX2011011964A (es) | 2009-05-12 | 2012-02-23 | Janssen Pharmaceuticals Inc | Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos. |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
AU2010246607B2 (en) | 2009-05-12 | 2012-09-27 | Addex Pharma S.A. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
TWI488851B (zh) | 2009-09-03 | 2015-06-21 | 必治妥美雅史谷比公司 | 作為鉀離子通道抑制劑之喹唑啉 |
AU2011209649A1 (en) | 2010-01-27 | 2012-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrazine kinase inhibitors |
AU2011209651A1 (en) | 2010-01-27 | 2012-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrimidine kinase inhibitors |
EP2528917B1 (en) | 2010-01-27 | 2016-10-19 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridines useful for the treatment of autoimmune, inflammatory or (hyper)proliferative diseases |
US8779150B2 (en) * | 2010-07-21 | 2014-07-15 | Hoffmann-La Roche Inc. | Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide |
JPWO2012015024A1 (ja) | 2010-07-29 | 2013-09-12 | 大正製薬株式会社 | エチニル−ピラゾール誘導体 |
WO2012062759A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
CN103261195B (zh) | 2010-11-08 | 2015-09-02 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
PL2649069T3 (pl) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2 |
US9447099B2 (en) * | 2011-10-04 | 2016-09-20 | Hoffmann-La Roche Inc. | Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine |
UA110995C2 (uk) * | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
LT6064B (lt) | 2012-10-15 | 2014-08-25 | Vilniaus Universitetas | Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai |
RU2015116749A (ru) | 2012-10-23 | 2016-12-20 | Ф. Хоффманн-Ля Рош Аг | Антагонисты mglu2/3 для лечения аутических расстройств |
MX2015010700A (es) | 2013-02-21 | 2017-01-23 | Calitor Sciences Llc | Compuestos heteroaromaticos como moduladores de la p13 cinasa. |
RS57602B1 (sr) * | 2013-02-28 | 2018-11-30 | Eisai R&D Man Co Ltd | Derivat tetrahidroimidazo[1,5-d][1,4]oksazepina |
JP6343600B2 (ja) | 2013-02-28 | 2018-06-13 | 武田薬品工業株式会社 | スルホニルクロライド化合物の製造法 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
AR097617A1 (es) | 2013-09-13 | 2016-04-06 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos del 2h-indazol |
GB2518873A (en) | 2013-10-03 | 2015-04-08 | Agency Science Tech & Res | Bicyclic alkyne derivatives and uses thereof |
TR201807881T4 (tr) | 2013-12-19 | 2018-06-21 | Idorsia Pharmaceuticals Ltd | Antibakteriyel 1h-ındazol ve 1h-ındol türevleri. |
HUE045610T2 (hu) | 2014-01-21 | 2020-01-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk |
EA033889B1 (ru) | 2014-01-21 | 2019-12-05 | Янссен Фармацевтика Нв | Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа |
MA39901A (fr) | 2014-04-23 | 2017-03-01 | Hoffmann La Roche | Antagonistes de mglu2/3 pour le traitement de troubles des facultés intellectuelles |
JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
JO3601B1 (ar) * | 2014-08-01 | 2020-07-05 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
EP3230286B1 (en) * | 2014-12-11 | 2019-02-20 | Janssen Pharmaceutica NV | 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of mglur2 receptors |
WO2017103182A1 (en) * | 2015-12-18 | 2017-06-22 | Janssen Pharmaceutica Nv | Radiolabelled mglur2/3 pet ligands |
EA037941B1 (ru) | 2015-12-18 | 2021-06-09 | Янссен Фармацевтика Нв | ЛИГАНДЫ mGluR2/3 ДЛЯ PET, МЕЧЕННЫЕ РАДИОАКТИВНЫМИ ИЗОТОПАМИ |
WO2018019758A1 (en) | 2016-07-26 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
WO2018019770A1 (en) | 2016-07-28 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
EP3275877A1 (en) | 2016-07-28 | 2018-01-31 | Basf Se | Herbicidal pyridine compounds |
CN106316864A (zh) * | 2016-08-22 | 2017-01-11 | 苏州天马精细化学品股份有限公司 | 4‑甲基‑3‑三氟甲基苯胺的制备方法 |
MX2019010354A (es) * | 2017-03-16 | 2019-10-22 | Jiangsu Hengrui Medicine Co | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. |
CN108003093A (zh) * | 2017-12-07 | 2018-05-08 | 山东汇盟生物科技有限公司 | 2-羟基-3-三氟甲基吡啶的制备方法 |
CN113773247A (zh) * | 2021-07-23 | 2021-12-10 | 无锡海伦生物科技有限公司 | 一种2-氨基-5-碘吡啶的制备方法 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH505543A (de) * | 1968-11-01 | 1971-04-15 | Ciba Geigy Ag | Schädlingsbekämpfungsmittel |
NL7109150A (pt) | 1970-07-06 | 1972-01-10 | ||
US4028374A (en) * | 1975-11-03 | 1977-06-07 | Morton-Norwich Products, Inc. | Antibacterial thiocyanatobenzothiazoles |
DE2656468A1 (de) | 1976-12-14 | 1978-06-15 | Boehringer Mannheim Gmbh | N-(benzthiazol-2-yl)-oxamidsaeure- derivate und verfahren zu ihrer herstellung |
US4178449A (en) * | 1978-04-17 | 1979-12-11 | American Cyanamid Company | Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines |
US4408047A (en) * | 1980-03-28 | 1983-10-04 | Merck & Co., Inc. | Imidazodiazines |
KR930005004B1 (ko) | 1985-04-15 | 1993-06-11 | 쟈안센 파아마슈우티카 엔. 부이. | 치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법 |
FI91859C (fi) | 1987-06-17 | 1994-08-25 | Eisai Co Ltd | Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi |
IL90337A0 (en) | 1988-05-24 | 1989-12-15 | Pfizer | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
WO1990015801A1 (en) | 1989-06-22 | 1990-12-27 | Pfizer Inc. | Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases |
DE59005183D1 (de) | 1989-11-10 | 1994-05-05 | Agrolinz Agrarchemikalien | Verfahren zur Herstellung reiner, unsymmetrisch disubstituierter Harnstoffe. |
DE69327572T2 (de) | 1992-05-21 | 2000-06-21 | Otsuka Pharma Co Ltd | Phosphonsäurediester-derivat |
EE04282B1 (et) | 1996-02-07 | 2004-04-15 | Janssen Pharmaceutica N.V. | Pürasoolpürimidiinid, nende valmistamine ja kasutamine ravimina ning neid sisaldav kompositsioon |
FR2753970B1 (fr) | 1996-10-01 | 1998-10-30 | Synthelabo | Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique |
DK0891978T3 (da) | 1997-07-18 | 2002-07-01 | Hoffmann La Roche | 5H-Thiazol(3,2-a)pyrimidinderivativer |
ES2256969T3 (es) | 1997-11-10 | 2006-07-16 | Bristol-Myers Squibb Company | Compuestos de benzotiazol inhibidores de proteina tirosina qauinasa. |
US6239152B1 (en) | 1998-01-23 | 2001-05-29 | Pharmacia & Upjohn Company | Oxazolidinone combinatorial libraries, compositions and methods of preparation |
WO2000018767A2 (en) | 1998-09-30 | 2000-04-06 | Neurogen Corporation | 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
WO2000059908A2 (en) * | 1999-04-06 | 2000-10-12 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
BR0014818A (pt) * | 1999-10-08 | 2002-06-18 | Gruenenthal Gmbh | Imidazo-3-il-aminas bicìclicas procedimento de preparação e medicamentos que contém como substância ativa pelo menos uma imidazo-3-il-amina bicìclica |
FR2801308B1 (fr) * | 1999-11-19 | 2003-05-09 | Oreal | COMPOSITIONS DE TEINTURE DE FIBRES KERATINIQUES CONTENANT DE DES 3-AMINO PYRAZOLO-[1,(-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES |
CN1234358C (zh) | 2000-06-21 | 2006-01-04 | 弗·哈夫曼-拉罗切有限公司 | 苯并噻唑衍生物 |
JP2002105085A (ja) * | 2000-09-28 | 2002-04-10 | Yamanouchi Pharmaceut Co Ltd | 新規イミダゾチアゾール誘導体 |
JP4077317B2 (ja) | 2000-12-04 | 2008-04-16 | エフ.ホフマン−ラ ロシュ アーゲー | グルタメート受容体アンタゴニストとしてのフェニルエテニルまたはフェニルエチニル誘導体 |
US6596731B2 (en) * | 2001-03-27 | 2003-07-22 | Hoffmann-La Roche Inc. | Substituted imidazo[1,2-A] pyridine derivatives |
KR100566171B1 (ko) | 2001-04-12 | 2006-03-29 | 에프. 호프만-라 로슈 아게 | mGluR2 길항제 Ⅱ인디하이드로-벤조[b][1,4]디아제핀-2-온 유도체 |
GB0128499D0 (en) | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
US6727247B2 (en) | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
US6713499B2 (en) | 2001-12-12 | 2004-03-30 | Hoffman-La Roche Inc. | 7-Amino-benzothiazole derivatives |
ES2300798T3 (es) | 2003-04-15 | 2008-06-16 | Astrazeneca Ab | Benzosulfonamidas sustituidas como potenciadores de los receptores de glutamato. |
BRPI0411350A (pt) * | 2003-06-12 | 2006-07-11 | Hoffmann La Roche | derivados de imidazol substituìdos por heteroarilas como antagonistas de receptores de glutamato |
US7329662B2 (en) | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
DE10357565A1 (de) * | 2003-12-10 | 2005-07-07 | Bayer Cropscience Ag | Pyrazolopyrimidine |
US20070191395A1 (en) * | 2004-02-16 | 2007-08-16 | Katsuhiro Kawakami | Heterocyclic compounds having antifungal activity |
WO2005123738A1 (en) | 2004-06-21 | 2005-12-29 | F.Hoffmann-La Roche Ag | Pyrrazolo-pyrimidine derivatives |
US7494984B2 (en) * | 2005-08-31 | 2009-02-24 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
BRPI0616571A2 (pt) * | 2005-09-27 | 2011-06-21 | Hoffmann La Roche | oxadiazolil pirazol-piridiminas como antagonistas de mglur2, processo para sua preparação, composição farmacêutica que os contém e uso dos mesmo |
AU2009211890B2 (en) * | 2008-02-05 | 2014-03-13 | Sanofi-Aventis | Imidazopyridazines as PAR1 inhibitors, production thereof, and use thereof as medicaments |
-
2006
- 2006-03-14 CA CA2602444A patent/CA2602444C/en active Active
- 2006-03-14 DK DK06723412.0T patent/DK1863818T3/da active
- 2006-03-14 KR KR1020077024199A patent/KR100973609B1/ko active IP Right Grant
- 2006-03-14 AT AT06723412T patent/ATE460417T1/de active
- 2006-03-14 MX MX2007011483A patent/MX2007011483A/es active IP Right Grant
- 2006-03-14 KR KR1020097013138A patent/KR100968989B1/ko active IP Right Grant
- 2006-03-14 EP EP06723412A patent/EP1863818B1/en active Active
- 2006-03-14 JP JP2008502284A patent/JP4801724B2/ja active Active
- 2006-03-14 PL PL06723412T patent/PL1863818T3/pl unknown
- 2006-03-14 CN CN2006800181208A patent/CN101180299B/zh active Active
- 2006-03-14 ES ES06723412T patent/ES2339477T3/es active Active
- 2006-03-14 PT PT06723412T patent/PT1863818E/pt unknown
- 2006-03-14 DE DE602006012815T patent/DE602006012815D1/de active Active
- 2006-03-14 WO PCT/EP2006/002334 patent/WO2006099972A1/en active Application Filing
- 2006-03-14 SI SI200630611T patent/SI1863818T1/sl unknown
- 2006-03-14 BR BRPI0609719A patent/BRPI0609719B8/pt active IP Right Grant
- 2006-03-14 AU AU2006226669A patent/AU2006226669B2/en active Active
- 2006-03-14 RU RU2007134899/04A patent/RU2412943C2/ru active
- 2006-03-15 US US11/375,834 patent/US7238808B2/en active Active
- 2006-03-20 TW TW095109515A patent/TWI314862B/zh active
- 2006-03-21 AR ARP060101092A patent/AR052948A1/es active IP Right Grant
-
2007
- 2007-03-23 US US11/726,807 patent/US7446113B2/en active Active
- 2007-09-03 IL IL185692A patent/IL185692A/en active IP Right Grant
- 2007-09-11 NO NO20074592A patent/NO340078B1/no unknown
- 2007-09-18 ZA ZA200708028A patent/ZA200708028B/xx unknown
-
2008
- 2008-08-12 US US12/189,895 patent/US7718661B2/en active Active
-
2010
- 2010-03-29 US US12/748,472 patent/US8063048B2/en active Active
- 2010-05-28 CY CY20101100474T patent/CY1110115T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0609719B8 (pt) | derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2 | |
BRPI0709633B8 (pt) | derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos | |
BRPI0607583A2 (pt) | derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos | |
BRPI0910439B8 (pt) | derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos | |
BRPI0517945A (pt) | derivados de quinuclidina e seu uso como antagonistas de receptor muscarìnico m3 | |
BRPI0507041A (pt) | composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos | |
BRPI0510453A (pt) | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central | |
BRPI0511072B8 (pt) | compostos derivados de alquinila como moduladores dos receptores de glutamato metabotróbico, seus usos e suas composições farmacêuticas | |
BRPI0717970C1 (pt) | composto inibidor de 11betahsd1, composição farmacêutica, e, uso do composto | |
BRPI0607577A2 (pt) | antagonistas cgrp, processo para sua preparação bem como seu uso como medicamento | |
BR112014008045A2 (pt) | benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas | |
BRPI0408347B8 (pt) | derivados de pirimidina, seu uso, e composição e combinação farmacêuticas | |
BR112015020772A2 (pt) | compostos de pirimidina e piridina e seu uso | |
BRPI0515081A (pt) | derivados de fenilaminopirimidina como inibidores de bcr-abl cinase | |
BRPI0606964A2 (pt) | pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5 | |
CY1112429T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
BR112013000254A2 (pt) | derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2 | |
BRPI0415683A (pt) | inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central | |
BR112015006737A2 (pt) | compostos de sulfonamida substituídos | |
BRPI0606437A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta | |
BRPI0817242A8 (pt) | compostos derivados de 1,1,1-trifluoro-2-hidroxi-3-fenilpropano, processo para a sua manufatura e composições farmacêuticas que os contêm | |
BRPI0410660A (pt) | derivados de 2-amino-piridina como agonistas de adrenoreceptor ß2 | |
BRPI0900983B8 (pt) | composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso | |
BRPI0518907A2 (pt) | compostos, processo para a sua manufatura, composiÇÕes farmacÊuticas que os compreendem, mÉtodo para o tratamento e/ou prevenÇço de enfermidades que estço associadas com a modulaÇço de receptores de h3 e sua utilizaÇço | |
BRPI0713443A2 (pt) | Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |